
Publication
Patenting biomarker-related AI / machine-learning innovations
Defining patent-eligible subject matter under 35 U.S.C. § 101 is an ongoing struggle for the United States Patent and Trademark Office.
The rapid convergence of digital technologies with healthcare over the past five years (even prior to the COVID-19 pandemic) has transformed how healthcare is delivered to the masses.
To learn more, visit our digital health and precision medicine site led by Roger Kuan.
Publication
Defining patent-eligible subject matter under 35 U.S.C. § 101 is an ongoing struggle for the United States Patent and Trademark Office.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025